Full-Time

Associate Director Real World Data Intelligence

Data Science, Real World Data

Formation Bio

Formation Bio

51-200 employees

AI-driven platform accelerates clinical-stage drug development

No salary listed

Boston, MA, USA + 1 more

More locations: New York, NY, USA

Hybrid

Hybrid with 3 in-office days per week; open to relocation to Boston or New York.

Bachelor's, Master's, PhD

Category
Data & Analytics (1)
Required Skills
LLM
Data Science
Machine Learning
Data Engineering

Get referred to Formation Bio

See people who can refer or advise you

Requirements
  • BSc or MSc in biomedical informatics, computational sciences, epidemiology, or a related quantitative field
  • 5+ years of industry experience working directly with real-world data (EHR/EMR, claims, registries, linked biobank data) in pharma, biotech, health tech, or consulting, with at least 2+ years in people management
  • Strong data engineering proficiency (pipelines, ingestion frameworks, data models, data lakes/marts) combined with deep working knowledge of biological and medical ontologies (ICD, SNOMED CT, MedDRA, RxNorm, ATC) and harmonization standards, particularly OMOP CDM
  • Demonstrated experience with RWD procurement and vendor management: evaluating data providers, negotiating agreements, and integrating new data assets
  • Proven ability to deliver RWD-derived insights across multiple drug development use cases (e.g., trial design, epidemiology, comparative effectiveness, label expansion), with familiarity across the development lifecycle from target selection through post-market
  • Proficiency with modern AI/ML tools, including large language models, and their applications in data engineering and harmonization workflows
  • Strong communication skills with the ability to translate complex data infrastructure concepts for clinical, scientific, and executive audiences
Responsibilities
  • Lead the RWD Intelligence function within Data Science, owning data strategy, sourcing, and delivery of analysis-ready datasets
  • Architect and maintain the supporting infrastructure (pipelines, ingestion workflows, data models, lakes/marts) across EHR/EMR, claims, registries, and genomics-linked cohorts
  • Drive adoption and extension of harmonization frameworks (e.g., OMOP CDM) across heterogeneous data sources, leveraging AI/ML tools for entity resolution, ontology mapping, data quality monitoring, and automated harmonization
  • Manage RWD vendor relationships end-to-end: evaluate providers, negotiate data use agreements, broker new partnerships, and integrate acquired datasets into the platform
  • Partner with Data Science, Clinical Development, Business Development, and Engineering teams to define RWD use cases (trial feasibility, synthetic control arms, epidemiology, label expansion) and productize ad hoc pipelines into scalable, production-grade systems
  • Foster a culture of data quality rigor, documentation, and reproducibility across all RWD assets
Desired Qualifications
  • PhD in biomedical informatics, epidemiology, computational biology, or a related field
  • Experience with large-scale biobank and genomics-linked RWD platforms (UK Biobank, FinnGen, All of Us), with a track record of building RWD infrastructure that directly influenced drug acquisition, licensing, or portfolio decisions
  • Familiarity with additional biomedical data modalities (scientific literature mining, -omics datasets, molecular data integration) and with data science/analytics methodologies applied to RWD (causal inference, trial simulation, propensity score methods)
  • Background transitioning data infrastructure from research/ad hoc to production-grade systems in regulated environments
  • Experience working at the intersection of data engineering, data science, and business strategy in pharma/biotech

Formation Bio uses an AI-driven platform to speed up drug development by focusing on clinical-stage assets. It acquires and advances these assets using flexible financing structures, aiming to shorten timelines and cut costs for bringing new drugs to market. The core product is the proprietary AI tools that help with drug selection, development planning, and improving overall efficiency, enabling partnerships and successful commercialization with pharmaceutical and biotech companies. Compared with competitors, Formation Bio combines a data-powered approach with adaptable financing and asset acquisition strategies to move assets forward quickly and cost-effectively. The goal is to make treatments more accessible and affordable by accelerating development and enabling faster, more predictable commercialization through AI-enhanced decision making and flexible funding options.

Company Size

51-200

Company Stage

Series D

Total Funding

$530.3M

Headquarters

New York City, New York

Founded

2013

Get referred to Formation Bio

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • June 2025 Series D raised $372 million, supporting pipeline expansion and platform buildout.
  • June 2026 BLKR201 entered Phase 1 five months after in-licensing, showing execution speed.
  • Formation Bio licensed IMIDomics anti-CD226 and Lynk BLKR201, broadening autoimmune assets.

What critics are saying

  • BLKR201 is first-in-human only; failure before early-2027 readout would damage platform claims.
  • Formation Bio depends on partners like Sanofi, Lynk, and IMIDomics for pipeline supply.
  • If gusacitinib or BLKR201 disappoint, the company becomes an expensive asset-flipping story.

What makes Formation Bio unique

  • Formation Bio pairs AI trial design with asset acquisitions and in-licensing.
  • Sanofi and OpenAI partnered with Formation Bio in June 2025 on AI drug development.
  • Michael Ehlers joined July 2026, adding Biogen and Pfizer R&D credibility.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Company Equity

Remote Work Options

Flexible Work Hours

Growth & Insights and Company News

Headcount

6 month growth

0%

1 year growth

0%

2 year growth

0%
PR Newswire
Jul 22nd, 2026
Formation Bio appoints Michael Ehlers as CSO to lead R&D strategy

Formation Bio has appointed Michael D. Ehlers as Chief Scientific Officer and Head of R&D. Ehlers will oversee portfolio strategy and advancement, from translational sciences through clinical development, and guide the scientific direction of Formation Bio's AI platform. Ehlers joins from MPM BioImpact, where he was an Entrepreneur Partner. He previously served as Executive Vice President of R&D at Biogen and held senior positions at Pfizer. Throughout his career, programmes under his leadership have produced six approved drugs spanning five indications and four drug modalities, with more than 40 programmes advanced into the clinic. Formation Bio is an AI-native pharma company that acquires clinical-stage assets and accelerates them through development using its proprietary AI platform.

PR Newswire
Jun 9th, 2025
Formation Bio Announces First Class Of Entrepreneurs In Residence To Drive Pipeline Growth And Strategic Partnerships

NEW YORK, June 9, 2025 /PRNewswire/ -- Formation Bio, an AI-driven pharmaceutical company focused on accelerating drug development, today announced the appointment of its first class of Entrepreneurs in Residence (EIRs): Kia Motesharei, Ph.D., Minji Kim Ph.D, MBA, John Taylor, M.S., and Anthony S. Walsh, D.Phil, These seasoned dealmakers will work closely with Chief Business Officer David Steinberg to expand the company's business development capabilities and further its mission to bring high-potential treatments to patients faster. Formation Bio acquires and in-licenses promising drug assets, advancing them through critical development milestones (Phase II and beyond), and then out-licensing for further advancement. The company's AI platform supports this lifecycle end-to-end—from asset identification and development strategy to execution of clinical trials aimed at greater speed and higher probability of success

Intelligence360 News
Jul 18th, 2024
Trialspark Dba Formation Bio Has Filed A Notice Of An Exempt Offering Of Securities To Raise $372,000,000.00 In New Equity Investment.

TrialSpark dba Formation Bio has filed a notice of an exempt offering of securities to raise $372,000,000.00 in New Equity Investment. TrialSpark dba Formation Bio has filed a notice of an exempt offering of securities to raise $372,000,000.00 in New Equity Investment.According to filings with the U.S. Securities and Exchange Commission, TrialSpark dba Formation Bio is raising up to $372,000,000.00 in new funding. Sources indicate that as part of senior management Chief Executive Officer, Benjamine Liu played a key role in securing the recent investment and it will aid in aggressively expanding the company, as well as broaden and accelerate product development.About TrialSpark dba Formation BioFormation Bio is a tech-driven pharmaceutical company differentiated by radically more efficient drug development. Formation Bio has built a technology platform that optimizes critical aspects of clinical drug development, enabling more efficient trial design, faster trial completion, and higher quality trial data. The company acquires clinical-stage drugs from pharmaceutical and biotech companies with the goal to develop them faster in order to accelerate access to new treatments for patients, and to unlock greater value per program.To learn more about TrialSpark dba Formation Bio, visit http://www.formation.bio/TrialSpark dba Formation Bio Linkedin Page: https://www.linkedin.com/company/formationbio/Contact:Benjamine Liu, Chief Executive Officer866-283-7544https://www.linkedin.com/in/benjamine-liu-54306518/SOURCE: http://www.intelligence360.ioCopyright (c) 2024 SI360 Inc

FinSMEs
Jun 26th, 2024
Formation Bio Raises $372M in Series D Funding

Formation Bio, a NYC-based tech-driven and AI-native pharma company, raised $372M in Series D funding

HIT Consultant
May 21st, 2024
Sanofi, Formation Bio, Openai Partner On Ai-Powered Drug Discovery

What You Should Know:– Sanofi, a global pharmaceutical leader, Formation Bio, an AI-powered drug developer, and OpenAI, a leading research and development company in artificial intelligence, have announced a groundbreaking collaboration. The first-of-its-kind partnership in the pharma and life sciences industries aims to leverage AI to accelerate drug development and bring new medicines to patients faster.– Sanofi, Formation Bio, and OpenAI believe this collaboration will be a game-changer in the pharmaceutical industry. By combining their expertise in data, AI technology, and drug development, they aim to revolutionize the way new medicines are discovered and brought to market.A Symphony of ExpertiseThe collaboration will combine the unique strengths of each partner:Sanofi: Will contribute proprietary data for building custom AI models, furthering their goal of becoming the first biopharma company powered by AI at scale. This data will be crucial for training and refining the AI tools used in drug discovery.Will contribute proprietary data for building custom AI models, furthering their goal of becoming the first biopharma company powered by AI at scale. This data will be crucial for training and refining the AI tools used in drug discovery. OpenAI: World-renowned for its advancements in AI technology, OpenAI will contribute access to cutting-edge AI capabilities